2026 Licensing Marketing 
Agency IQ
JANUARY 4, 2024
Swissmedic reorg adds new focus on medical device market surveillance The Swiss regulator, Swissmedic, just announced a reorganization, with a new head of the medicinal product authorization and vigilance sector, but also a new and discrete medical devices surveillance sector. KAROLINE MATHYS is the head of the new sector.
The Pharma Data
SEPTEMBER 7, 2021
0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. and Citigroup Global Markets Inc. toll-free at +1 (888) 292-0070 or collect at +1 (980) 387-3907 or to Citigroup Global Markets Inc. 3.950% Notes due 2049. 532457 BT4. 1,500,000,000. 532457 AM0.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
AUGUST 16, 2024
The June 2023 guidance recommends that studies involve two monitors (one with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently) to observe study participants during treatment sessions. The study is planned to begin in 2026 and conclude in 2028.
Drug Discovery World
SEPTEMBER 6, 2022
Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The challenge for the market then, according to Boissel, is how much can a payor afford to pay upfront? . Workforce .
Agency IQ
AUGUST 2, 2024
While generic drugs technically pre-dated the law (look up “Paper NDAs” if you’re interested), the law turbocharged the ability of generics to come to market. While this would not affect existing vouchers, it would prevent FDA from issuing new ones after September 2026. Read the full list of documents on FDA’s Unified Agenda here.]
Agency IQ
JULY 26, 2024
BY LAURA DIANGELO, MPH , RACHEL COE, MSC | JUL 23, 2024 9:54 PM CDT Biosimilarity and interchangeability: A quick recap The Biologics Price Competition and Innovation (BPCI) Act of 2009 intended to increase the number of biologic products on the market by creating two types of approvals for biosimilar products.
The Pharma Data
DECEMBER 12, 2020
The success of the franchise is demonstrated by the effective transition of over 70% of PNH patients from Soliris to Ultomiris in less than two years of launch in its key markets, including the US, Japan and Germany , as well as the strong pipeline of additional indications for Ultomiris. 2 EvaluatePharma, World Preview 2020, Outlook to 2026.
Expert insights. Personalized for you.
40 
Let's personalize your content